BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 (Anti-Factor VIII) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery.

The Phase IIb study is a multicenter, double blind, randomised controlled trial. It is comparing the safety and efficacy of two dose levels of TB-402, given as a single intravenous infusion after hip surgery, with the recently approved Factor Xa inhibitor rivaroxaban. The trial will enrol 600 patients across 41 centers in Europe. Results are expected in the second half of 2012.

TB-402 is a recombinant human monoclonal antibody that has a novel mode of action. It targets Factor VIII, a key component of the coagulation cascade. An important benefit of TB-402 is that a single injection could provide a stable, long-acting antithrombotic effect, for the prophylaxis of VTE after orthopaedic surgery, which is expected to lead to reduced nursing time and improved patient compliance.

Importantly, TB-402's anti-coagulant activity is easily reversible using Factor VIII, in case of bleeding or need for surgery. In contrast, certain newer anticoagulant therapies lack an antidote which can make it difficult to manage serious bleeds or which may complicate or delay acute surgical procedures.

In 2010, TB-402 reported positive results in a 315-patient Phase IIa trial for VTE prophylaxis after knee replacement surgery, compared with enoxaparin, the standard treatment for preventing VTE in this setting. The positive pooled results of three doses of TB-402 (0.3 mg/kg, 0.6 mg/kg and 1.2 mg/kg) showed a 22% incidence of total VTE compared with 39% for enoxaparin (p<0.05). In addition, TB-402 was generally well tolerated and demonstrated comparable safety to enoxaparin. The results were published in the Journal of Thrombosis and Haemostasis in February 2011.

Dr. Patrik De Haes, CEO of ThromboGenics, commenting on the announcement said: "TB-402 has already shown the potential to significantly improve the treatment of VTE in the post-surgery setting. We hope that this study will confirm these promising results and give us a better understanding of the overall benefits that TB-402 can provide to this patient group. We believe that VTE prophylaxis with a single dose of TB-402 that lasts for several weeks is a simple and attractive option for physicians and patients when compared with other anticoagulant regimes that are currently available."

Svein Mathisen, CEO of BioInvent, added: "We are delighted about the product's demonstrated success in earlier trials and believe that it represents an innovative approach to the prevention of VTE after hip orthopaedic surgery. TB-402 promises to become a very important entrant into the anticoagulant market where the product would fill a significant unmet need."

Source:

ThromboGenics NV

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers boost natural defenses to fight cataracts and delay the need for surgery